Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, October 12th. The shares were sold at an average price of $158.46, for a total value of $31,692.00. Following the sale, the executive vice president now owns 25,172 shares of the company’s stock, valued at $3,988,755.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Michael Patrick Miller also recently made the following trade(s):

  • On Friday, September 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $165.20, for a total value of $33,040.00.
  • On Tuesday, August 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $175.70, for a total value of $35,140.00.

Shares of NASDAQ JAZZ opened at $158.86 on Thursday. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 16.62, a price-to-earnings-growth ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals PLC has a 12 month low of $128.58 and a 12 month high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.23 by $0.26. The company had revenue of $500.48 million for the quarter, compared to the consensus estimate of $469.85 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. On average, research analysts forecast that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current fiscal year.

JAZZ has been the topic of a number of recent analyst reports. BMO Capital Markets raised their price objective on Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, August 8th. Mizuho reissued a “neutral” rating and issued a $173.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Sunday, July 8th. BidaskClub downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 18th. Finally, Citigroup raised their price objective on Jazz Pharmaceuticals from $162.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. Jazz Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $193.32.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC increased its position in Jazz Pharmaceuticals by 12.1% in the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after buying an additional 715,595 shares during the period. BlackRock Inc. increased its position in Jazz Pharmaceuticals by 64.0% in the 2nd quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock worth $753,311,000 after buying an additional 1,706,417 shares during the period. Partner Fund Management L.P. increased its position in Jazz Pharmaceuticals by 9.1% in the 2nd quarter. Partner Fund Management L.P. now owns 1,238,906 shares of the specialty pharmaceutical company’s stock worth $213,464,000 after buying an additional 103,379 shares during the period. Boston Partners increased its position in Jazz Pharmaceuticals by 1.8% in the 2nd quarter. Boston Partners now owns 1,089,656 shares of the specialty pharmaceutical company’s stock worth $187,748,000 after buying an additional 18,821 shares during the period. Finally, Wells Fargo & Company MN increased its position in Jazz Pharmaceuticals by 10.5% in the 2nd quarter. Wells Fargo & Company MN now owns 510,150 shares of the specialty pharmaceutical company’s stock worth $87,898,000 after buying an additional 48,455 shares during the period. 92.52% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: How to Use a Moving Average for Trading 

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply